Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bhag Karamchandani who wrote (4508)	6/17/1998 11:40:00 PM
From: Bhag Karamchandani	Read Replies (2) of 6136

Re: AG3340; AGPH latest statement begs the question: What happened to the majority (close to 75 % 0f the patients (47 in total)) who were not included in the "stabilized" category?? Was period of treatment with AG3340 a factor?? Also are there any early indications of how AG3340 works with non- advanced ( again how does AGPH or anyone define advanced ) cancers? Is the glass one-third full and two thirds empty or vice versa???? I found the press release quite ambiguous. Hope it was not deliberate. Is the reference to second generation MMP a way to play down expectations re AG 3340? Very much hope we do not have another Thymatiq unfolding. Why not simply publish the statistical data summary????

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next